Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00399763 · ClinicalTrials.gov registry record · NA

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

A NA study of Attention Deficit Hyperactivity Disorder and Substance Abuse, sponsored by Denver Health and Hospital Authority.

Completed
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT00399763 is a NA study of Attention Deficit Hyperactivity Disorder and Substance Abuse that has completed, run by Denver Health and Hospital Authority. The registered enrollment target is 70 participants, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00399763, a NA study of Attention Deficit Hyperactivity Disorder and Substance Abuse, has completed, sponsored by Denver Health and Hospital Authority.

COMPLETED
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.

Interventions

  • DRUG Placebo
  • DRUG Atomoxetine

Study Locations (1)

Colorado

  • Denver Health Medical Center - Denver

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2005-09
Est. Completion 2008-02
Phase NA

What the Registry Record Tells You About NCT00399763

The ClinicalTrials.gov registry entry for NCT00399763 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (66% lower). The listed sponsor is Denver Health and Hospital Authority, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00399763 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT00399763 about?

NCT00399763 is a clinical study titled "Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder". The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.

What is the current status of trial NCT00399763?

This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2005-09. Estimated completion is 2008-02.

What conditions does trial NCT00399763 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, Substance Abuse.

What interventions are being tested in trial NCT00399763?

The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG).

Who is sponsoring clinical trial NCT00399763?

This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00399763 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.